Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) is now available.
Pharmaron Beijing Co., Ltd. has established a Remuneration and Appraisal Committee to enhance its governance structure by formulating appraisal standards and remuneration policies for its directors and senior management. This initiative aims to optimize corporate governance and ensure accountability within the company’s leadership, potentially strengthening its industry position and stakeholder trust.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. operates in the pharmaceutical industry, focusing on providing comprehensive drug research and development services. The company is known for its expertise in drug discovery, preclinical, and clinical development services, catering to a global market.
Average Trading Volume: 13,234,723
Technical Sentiment Signal: Buy
Current Market Cap: HK$59.02B
Find detailed analytics on 3759 stock on TipRanks’ Stock Analysis page.